This year’s Current Process Chemistry meeting reflected innovation, good science and superb attendee interaction
CHI’s Current Process Chemistry meeting took place June 13-14, 2012 in Princeton, New Jersey. The event, now in its sixth year, featured more than 20 presentations, poster and networking sessions and an expert panel on Chemical Development Partnering. Attendees were from all facets of the drug development industry (‘big pharma’ companies (40%), ,smaller and mid-sized biopharma companies and (20%?) and service provider companies who offer process chemistry/chemical development partnerships (40%).
Coverage this year included, Case Studies of API Synthesis, Regulatory Challenges, Flow/Continuous Processing, and Process Planning.
Current Process Chemistry featured two full days of programming, two pre-conference short courses, as well as heavily attended breakout discussion groups.
Hear what people said about this year’s Current Process Chemistry:
“Met my expectations. Has a potential to be a key conference for CMC development colleagues in the pharma industry”
Dr. Sandeep M., Director, Pharmaceutical Dev Operations, Bristol-Myers Squibb Co.
“Innovation in action. Sums up this year’s Process Chemistry conference organized by CHI”
Dr. Ambarish S., Director, Chemistry Mfg & Control, Bristol-Myers Squibb Co.
“The intimate setting is ideal for facilitating productive interaction with your peers & colleagues”
Dr. Scott D., Sr Mgr API Dev & Process Chemistry, Alkermes Inc
“A great combination of good science & practical industry perspective”
Dale M., Process Chemist, Teva Pharmaceuticals
“A focussed group with a diversified background. The interaction among the attendees was superb”
Dr. Shen D., Sr Principal Scientist, Pfizer
“The topics were spot on and timely, especially the case studies concerning the development of workable and scalable routes & processes in this ‘challenging’ environment of diminishing resources, constant restructuring and accelerated time schedules. I liked the mix of topics, going from case studies to expert presentations to roundtables. More enjoyable than just two days of detailed case studies.”
Dr. Harlan R,, ProcessResearch & Synthesis, Roche
Strategies and Innovations Toward the Rapid Development of the Cobicistat Drug Substance
Richard Yu, Ph.D., Director, Process Development, Gilead Sciences, Inc.
The presentation will highlight the accelerated development of the cobicistat drug substance. The discussion will feature the integration of process research and development plans, innovations, and regulatory strategies taken throughout the lifecycle of the program up to the marketing approval application.
- Case Studies of API Synthesis
- Regulatory Challenges
- Focus on Flow/Continuous Processing
- Process Planning
- Case Studies II
Neal Anderson, Ph.D., President, Anderson’s Process Solutions
Matthew Ravn, Ph.D., Senior Scientist III, GPRD Process R&D, Abbott
Ambarish Singh, Ph.D., Associate Director, CMC, Bristol-Myers Squibb
Pre-conference Short Courses*
Refining API Process Development for This Decade
Instructor: Neal Anderson, Ph.D., President,
Anderson’s Process Solutions
Incorporating Continuous Flow Chemistry
Nicholas Leadbeater, Ph.D., Associate Professor, Chemistry,
University of Connecticut
Bryan Li, Ph.D., Associate Research Fellow, Chemical R&D,
Pfizer Pharmaceutical Science
Timothy Braden, Process Chemist, Continuous Chemistry Group, Chemical Product R&D, Eli Lilly and Company
*Separate registration required
Antonio Montalban, Ph.D., Director, Chemical R&D, Arena Pharmaceuticals
Jay Srirangam, Ph.D., Associate Research Fellow, World Wide Phamraceutical Sciences, Pfizer
Sandeep P. Modi, Ph.D., Group Director, CMC Documentation – Pharmaceutical Development, Bristol-Myers Squibb Co.